OSEBX1 931,13−0,72 %
EQNR338,50−3,26 %
DNB282,30+0,43 %
MOWI198,90−1,63 %
Brent$99,13−2,11 %
Gold$4 743,40+1,05 %
USD/NOK9,2137−0,93 %
EUR/NOK10,8485−0,71 %
SPX7 365,12+0,00 %
NDX28 599,17+0,00 %
LIVE · 10:11 UTC
BFNH.PK56

BioForce Nanosciences Holdings Inc

Miscellaneous Specialty RetailersVerified
Score breakdown
Profitability+3Sentiment+24Missing signals-3
Quality breakdown
Key fields100Profile38Conclusion97AI synthesis40Observations3

Capital Structure and Liquidity BioForce Nanosciences Holdings Inc. has a negative total equity of -$618,540 and a current ratio of 0, indicating severe liquidity constraints [doc:BFNH-103]. The company has no long-term debt, but its operating cash flow is negative at -$65,150, further highlighting its inability to generate cash from operations [doc:BFNH-104]. The liquidity risk is rated as low, but this appears to be based on the absence of immediate filing-based flags rather than strong liquidity metrics [doc:BFNH-105]. ### Profitability and Returns The company reported a net loss of -$1,291,950 and an operating loss of the same amount, indicating a lack of profitability [doc:BFNH-106]. The return on equity is 2.09, but this is misleading due to the negative equity base [doc:BFNH-107]. The return on assets is -1,635.38, reflecting a significant underperformance relative to asset utilization [doc:BFNH-108]. These metrics are far below the industry median for profitability and returns, suggesting a weak financial position. ### Segments and Geographic Exposure BioForce operates as a single business segment, marketing nutritional supplements through social media, telemarketing, and direct sales on its website [doc:BFNH-109]. The company's primary geographic exposure is the United States, with no disclosed international operations [doc:BFNH-110]. The company's revenue concentration is entirely within its own product lines, with no diversification across segments or geographies [doc:BFNH-111]. ### Growth Trajectory The company has reported zero revenue, indicating no current sales activity [doc:BFNH-112]. With no revenue history to analyze, it is difficult to assess growth trajectory. The outlook for the current and next fiscal years is not provided, but the lack of revenue and profitability suggests a high risk of continued losses [doc:BFNH-113]. ### Risk Factors The company faces significant financial risks, including negative equity and operating cash flow [doc:BFNH-114]. The dilution risk is rated as low, but the company has a large number of shares outstanding (33,521,755), which could dilute future earnings if new shares are issued [doc:BFNH-115]. No immediate filing-based liquidity or dilution flags were detected, but the financial position remains precarious [doc:BFNH-116]. ### Recent Events No recent filings or transcripts were provided in the input data to assess recent events or management commentary [doc:BFNH-117].

Profile
CompanyBioForce Nanosciences Holdings Inc
TickerBFNH.PK
SectorConsumer Cyclicals
BusinessRetailers
Industry groupRetailers
IndustryMiscellaneous Specialty Retailers
AI analysis

Business. BioForce Nanosciences Holdings, Inc. is a provider of natural vitamins, minerals, and other nutritional supplements, powders, and beverages, formulated to promote a healthier lifestyle for active individuals in all age ranges [doc:BFNH-101].

Classification. BioForce is classified under the Consumer Cyclicals economic sector, Retailers business sector, and Miscellaneous Specialty Retailers industry with a confidence level of 0.92 [doc:BFNH-102].

### Capital Structure and Liquidity BioForce Nanosciences Holdings Inc. has a negative total equity of -$618,540 and a current ratio of 0, indicating severe liquidity constraints [doc:BFNH-103]. The company has no long-term debt, but its operating cash flow is negative at -$65,150, further highlighting its inability to generate cash from operations [doc:BFNH-104]. The liquidity risk is rated as low, but this appears to be based on the absence of immediate filing-based flags rather than strong liquidity metrics [doc:BFNH-105]. ### Profitability and Returns The company reported a net loss of -$1,291,950 and an operating loss of the same amount, indicating a lack of profitability [doc:BFNH-106]. The return on equity is 2.09, but this is misleading due to the negative equity base [doc:BFNH-107]. The return on assets is -1,635.38, reflecting a significant underperformance relative to asset utilization [doc:BFNH-108]. These metrics are far below the industry median for profitability and returns, suggesting a weak financial position. ### Segments and Geographic Exposure BioForce operates as a single business segment, marketing nutritional supplements through social media, telemarketing, and direct sales on its website [doc:BFNH-109]. The company's primary geographic exposure is the United States, with no disclosed international operations [doc:BFNH-110]. The company's revenue concentration is entirely within its own product lines, with no diversification across segments or geographies [doc:BFNH-111]. ### Growth Trajectory The company has reported zero revenue, indicating no current sales activity [doc:BFNH-112]. With no revenue history to analyze, it is difficult to assess growth trajectory. The outlook for the current and next fiscal years is not provided, but the lack of revenue and profitability suggests a high risk of continued losses [doc:BFNH-113]. ### Risk Factors The company faces significant financial risks, including negative equity and operating cash flow [doc:BFNH-114]. The dilution risk is rated as low, but the company has a large number of shares outstanding (33,521,755), which could dilute future earnings if new shares are issued [doc:BFNH-115]. No immediate filing-based liquidity or dilution flags were detected, but the financial position remains precarious [doc:BFNH-116]. ### Recent Events No recent filings or transcripts were provided in the input data to assess recent events or management commentary [doc:BFNH-117].
Key takeaways
  • BioForce Nanosciences Holdings Inc. is a specialty retailer in the nutritional supplements space with no current revenue and significant financial losses.
  • The company has negative equity and operating cash flow, indicating severe liquidity and solvency issues.
  • The company's business model is concentrated in a single product line and geographic market, with no diversification.
  • The company's financial position is weak, with a high risk of continued losses and no clear path to profitability.
  • No recent events or filings were provided to assess management's strategy or operational progress.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyUSD
Revenue$0.00
Gross profit$0.00
Operating income-$1.3M
Net income-$1.3M
R&D
SG&A
D&A
SBC
Operating cash flow-$65.2k
CapEx
Free cash flow
Total assets$790.00
Total liabilities$619.3k
Total equity-$618.5k
Cash & equivalents
Long-term debt$0.00
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book-$618.5k
Net cash
Current ratio0.0
Debt/Equity-0.0
ROA-1635.4%
ROE2.1%
Cash conversion5.0%
CapEx/Revenue
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskLow
  • No immediate filing-based liquidity or dilution flags were detected.
Industry benchmarks
Activity: Retailers · cohort 8 companies
MetricBFNH.PKActivity
Op margin9.5% medp25 6.4% · p75 13.1%
Net margin8.2% medp25 5.0% · p75 11.1%
Gross margin35.0% medp25 33.0% · p75 44.8%
R&D / revenue0.4% medp25 0.4% · p75 0.4%
CapEx / revenue3.4% medp25 2.9% · p75 4.6%
Debt / equity-0.0%25.8% medp25 3.1% · p75 69.4%bottom quartile
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-04 08:48 UTC#97f85ee8
Source: analysis-pipeline (hybrid)Generated: 2026-05-04 08:49 UTCJob: 86fbed97